Broncho-adventitial Drug Delivery: Paclitaxel for Bronchial Carcinoma

Information

  • Research Project
  • 8652946
  • ApplicationId
    8652946
  • Core Project Number
    R42CA141907
  • Full Project Number
    3R42CA141907-03S1
  • Serial Number
    141907
  • FOA Number
    PA-12-100
  • Sub Project Id
  • Project Start Date
    5/1/2013 - 11 years ago
  • Project End Date
    8/31/2016 - 8 years ago
  • Program Officer Name
    LOU, XING-JIAN
  • Budget Start Date
    9/18/2013 - 11 years ago
  • Budget End Date
    8/31/2016 - 8 years ago
  • Fiscal Year
    2013
  • Support Year
    03
  • Suffix
    S1
  • Award Notice Date
    9/13/2013 - 11 years ago

Broncho-adventitial Drug Delivery: Paclitaxel for Bronchial Carcinoma

The major goals of interventional pulmonology are to improve breathing while minimizing infections through minimally invasive procedures within the airways. In patients with compromised airways, the daily struggle to breath can be extremely difficult even with supplemental oxygen. A partial relief of airway obstruction can have remarkable effects on symptoms and quality of life. Mercator has developed, as part of this STTR research and in collaboration with Beth Israel Deaconess Medical Center and Steward St. Elizabeth¿s Medical Center in Boston, MA, the Blowfish¿ Transbronchial Micro-Infusion Catheter to enable precision drug delivery to airway walls. Prior to the techniques developed in this project, drugs were administered to bronchi with swabs or crude biopsy needles. Treatment options for bronchial carcinoma over the past two decades have grown to include chemotherapy, radiation therapy, surgical resection, photodynamic therapy (PDT), argon plasma coagulation (APC), brachytherapy, and laser resection. Each of these therapeutic options carries risks and leads to recurrence of malignant airway obstruction often within 2 months of the therapy. Our goal is to minimize risks of localized treatment of carcinoma in situ associated with PDT, laser, APC therapies, etc. but offer similar benefit. Local bronchial wall delivery of drugs can also be an important treatment as adjuvant therapy for metastatic or benign diseases that cause airway narrowing.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R42
  • Administering IC
    CA
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    213437
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:213437\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    MERCATOR MEDSYSTEMS, INC.
  • Organization Department
  • Organization DUNS
    103706391
  • Organization City
    EMERYVILLE
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    946081813
  • Organization District
    UNITED STATES